Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2020

May 2020 | 30 pages | ID: P04AC3E969BEN
Global Markets Direct

Abstracts

Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Multifocal Leukoencephalopathy – Pipeline Review, H1 2020, provides an overview of the Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline landscape.

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by lytic infection of oligodendrocytes by the JC polyomavirus. Symptoms include clumsiness, progressive weakness, and visual, speech, and sometimes personality changes. Risk factors include the presence of pathogenic JCV and an altered or weakened immune system, genetic or environmental factors.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Multifocal Leukoencephalopathy – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 4 and 3 respectively.

Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Multifocal Leukoencephalopathy (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Progressive Multifocal Leukoencephalopathy - Overview
Progressive Multifocal Leukoencephalopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Progressive Multifocal Leukoencephalopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Progressive Multifocal Leukoencephalopathy - Companies Involved in Therapeutics Development
Biological E Ltd
Evrys Bio
Excision BioTherapeutics Inc
Humabs BioMed SA
Inhibikase Therapeutics Inc
Neurimmune Holding AG
Pomona Ricerca SRL
Progressive Multifocal Leukoencephalopathy - Drug Profiles
EBT-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IkT-01427 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for John Cunningham Infections and Progressive Multifocal Leukoencephalopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-307 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PNJC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Progressive Multifocal Leukoencephalopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Progressive Multifocal Leukoencephalopathy - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Progressive Multifocal Leukoencephalopathy - Pipeline by Biological E Ltd, H1 2020
Progressive Multifocal Leukoencephalopathy - Pipeline by Evrys Bio, H1 2020
Progressive Multifocal Leukoencephalopathy - Pipeline by Excision BioTherapeutics Inc, H1 2020
Progressive Multifocal Leukoencephalopathy - Pipeline by Humabs BioMed SA, H1 2020
Progressive Multifocal Leukoencephalopathy - Pipeline by Inhibikase Therapeutics Inc, H1 2020
Progressive Multifocal Leukoencephalopathy - Pipeline by Neurimmune Holding AG, H1 2020
Progressive Multifocal Leukoencephalopathy - Pipeline by Pomona Ricerca SRL, H1 2020
Progressive Multifocal Leukoencephalopathy - Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Biological E Ltd
Evrys Bio
Excision BioTherapeutics Inc
Humabs BioMed SA
Inhibikase Therapeutics Inc
Neurimmune Holding AG
Pomona Ricerca SRL